Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis.

@article{Montini1990BenefitsAR,
  title={Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis.},
  author={Giovanni Montini and Graziella Zacchello and Eugenio Baraldi and Stefania Zanconato and Agnese Suppiej and Fabrizio Giuseppe Menchini Fabris and Barbara Andreetta and Lucia Pavanello and Franco Zacchello},
  journal={The Journal of pediatrics},
  year={1990},
  volume={117 4},
  pages={
          556-60
        }
}
Ten children with renal failure (age range 2 years 6 months to 18 years 9 months; median 11 years 10 months), maintained by long-term hemodialysis, had successful correction of their anemia after intravenous administration of recombinant human erythropoietin in a dosage escalating every 2 weeks (75 to 150 to 300 to 450 IU/kg/wk). Mean hemoglobin concentration increased from 6.4 +/- 0.9 to 11.5 +/- 1.0 gm/dl. Blood cell counts used to evaluate the correction of anemia were done after dialysis… CONTINUE READING
19 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…